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Transmissible spongiform encephalopathies are fatal
neurodegenerative diseases associated with the accu-
mulation of a protease-resistant form of the prion pro-
tein (PrP). Although PrP is conserved in vertebrates, its
function remains to be identified. In vitro PrP binds
large nucleic acids causing the formation of nucleopro-
tein complexes resembling human immunodeficiency vi-
rus type 1 (HIV-1) nucleocapsid-RNA complexes and in
vivo MuLV replication accelerates the scrapie infectious
process, suggesting possible interactions between retro-
viruses and PrP. Retroviruses, including HIV-1 encode a
major nucleic acid binding protein (NC protein) found
within the virus where 2000 NC protein molecules coat
the dimeric genome. NC is required in virus assembly
and infection to chaperone RNA dimerization and pack-
aging and in proviral DNA synthesis by reverse tran-
scriptase (RT). In HIV-1, 5*-leader RNA/NC interactions
appear to control these viral processes. This prompted
us to compare and contrast the interactions of human
and ovine PrP and HIV-1 NCp7 with HIV-1 5*-leader
RNA. Results show that PrP has properties characteris-
tic of NCp7 with respect to viral RNA dimerization and
proviral DNA synthesis by RT. The NC-like properties of
huPrP map to the N-terminal region of huPrP. Interest-
ingly, PrP localizes in the membrane and cytoplasm of
PrP-expressing cells. These findings suggest that PrP is
a multifunctional protein possibly participating in nu-
cleic acid metabolism.
Transmissible spongiform encephalopathies are fatal neuro-
degenerative diseases that include Creutzfeld-Jakob disease,
kuru, fatal familial insomnia, and Gerstmann-Stra¨ussler-
Scheinker (GSS)1 syndrome in humans, scrapie in sheep and
goats, and bovine spongiform encephalopathy in cattle (1). A
major characteristic of transmissible spongiform encephalopa-
thy diseases is the accumulation of an abnormal partially pro-
tease-resistant prion protein (PrPSC), which is derived from the
normal protease-sensitive prion protein (PrPC). Although accu-
mulation of PrPSC may damage cells of the central nervous
system, it is clear that the generation of spongiform encepha-
lopathy requires the presence of both PrPSC and PrPC (2). The
abnormal PrPSC is thought to recruit the normal PrPC through
a proposed trans-conformation process causing the accumula-
tion of PrPSC in the form of plaques and fibrils (3–5).
The cellular prion protein (PrP) is encoded by a single gene
corresponding to about 250 amino acids and is highly conserved
in vertebrates (4–6). PrP is widely expressed, but it appears to
accumulate in the central nervous system and the lymphore-
ticular system. PrP may be produced via several pathways,
because it can be found in the extracellular fluid, on the outer
surface of the plasma membrane and Golgi, and as a trans-
membrane form, designated ctmPrP, where the N-terminal
domain is oriented within the cytoplasm (7, 8). In addition, a
truncated version of PrP, resulting from a stop codon at posi-
tion 145 in human PrP (huPrP), is associated with a variant of
the GSS syndrome and is found in the cytoplasm (9).
Although PrP is a highly conserved protein in vertebrates, its
role remains to be identified. Interestingly, PrP null mice de-
velop normally and appear to be healthy (2). Nonetheless, a
number of functions have been proposed for PrP such as super-
oxide dismutase activity, involvement in copper metabolism
(reviewed in Ref. 10), and, very recently, participation in signal
transduction during neuronal differentiation (11). In addition,
PrP was shown to interact with sulfated glycans (12), RNA
aptamers (13), and large nucleic acids (14, 15), causing the
formation of nucleoprotein complexes similar to HIV-1 nucleo-
capsid-RNA complexes formed in vitro (16). A recent report
shows that MuLV replication accelerates the scrapie infectious
process (17), suggesting possible in vivo interactions between
retroviruses and PrP.
These findings prompted us to compare and contrast the
interactions of human PrP and the HIV-1 Gag-encoded nucle-
ocapsid protein with viral nucleic acids. HIV-1, like all retro-
viruses examined to date (except for the Spumaretroviruses),
encodes a major nucleic acid binding protein (NC protein)
found in the virion core where about 2000 NC protein molecules
completely coat the dimeric RNA genome. The biological roles
of NC include the chaperoning of RNA dimerization and pack-
aging during virus assembly and proviral DNA synthesis by
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reverse transcriptase (RT) in the course of viral infection.
These functions of NC are thought to be largely governed by
interactions with the HIV-1 59-leader RNA (16, 18–20).
Our results show that huPrP largely mimics the chaperone
properties of NCp7 with respect to the annealing of comple-
mentary nucleic acid strands, viral RNA dimerization, the
hybridization of replication primer tRNA3
Lys to the HIV-1
59-primer binding site sequence and the initiation of reverse
transcription by RT. These NC-like activities of huPrP appear
to map to the N-terminal region of huPrP. Such properties are
not unique to huPrP, because the ovine PrP was also found to
harbor nucleic acid-chaperoning properties similar to those of
HIV-1 NCp7 and retroviral nucleocapsid proteins (reviewed in
Ref. 16).
EXPERIMENTAL PROCEDURES
Recombinant Proteins, Enzymes, RNA, and Plasmid DNA—The full-
length human PrP (huPrP), and the fragments huPrP-(23–144)
(N-terminal region) and huPrP-(122–231) (C-terminal region) were pro-
duced in Escherichia coli and purified as described previously (21). The
ovine PrP (ovPrP) (residues 25–234) was prepared using a similar
protocol (22). The purity of the proteins was higher than 95% as judged
by polyacrylamide gel electrophoresis. HIV-1 nucleocapsid protein
NCp7, NCp7-(12–53), and Vpr were synthesized by the Fmoc (N-(9-
fluorenyl)methoxycarbonyl)/opfp chemical method and purified by high
pressure liquid chromatography (23). Proteins were dissolved at 1
mg/ml in buffer containing 30 mM Hepes, pH 6.5, 30 mM NaCl, and 0.1
mM ZnCl2. DNA oligonucleotide corresponding to the Tar(2) 57 nt of
HIV-1 sequences (pNL4.3 molecular clone) was from Eurogentec (Bel-
gium). HIV-1 59-leader RNA corresponding to nucleotides 1–415 was
generated in vitro as previously described (18) and phenol and chloro-
form extracted and purified by gel filtration. HIV-1 39-RNA of 650 nt
(positions 8583–9208 of the HIV-1 genome) with a poly(A) tail was
prepared by transcription in vitro (27).
Natural bovine tRNA3
Lys from beef liver was a kind gift of Ge´rard
Keith (Strasbourg, France). Synthetic tRNA3
Lys was generated in vitro
using T7 RNA polymerase. HIV-1 reverse transcriptase (RT p66/p51),
purified from E. coli, was provided by S. Le Grice (Frederick, MD).
HIV-1 integrase (INp32), purified from E. coli, was provided by J.-F.
Mouscadet (Villejuif, France).
All plasmid DNAs were amplified in E. coli 1035 (RecA2) and puri-
fied by affinity chromatography (Qiagen protocol).
Nucleoprotein Complex Formation—Reactions with HIV-1 32P-la-
beled 59-RNA, and either PrP or HIV-1 NCp7 were performed for 10 min
at 37 °C in 10 ml of a buffer containing 20 mM TriszHCl, pH 7.5, 30 mM
NaCl, 0.2 mM MgCl2, 5 mM dithiothreitol, 0.01 mM ZnCl2, and 1.5 pmol
of RNA. PrP or NCp7 was at the indicated molar protein to nucleotide
ratios. Reactions were stopped by 5 mM EDTA, and samples were
electrophoresed on a 1.3% agarose gel in 50 mM Triszborate, pH 8.3. Gels
were visualized by ethidium bromide staining followed by gel fixation in
5% trichloroacetic acid, drying, and autoradiography. To pellet nucleo-
protein complexes, reaction mixtures were centrifuged at 4 °C for 5 min
at 10,000 3 g.
Nucleic Acid Annealing Assays—Reactions with HIV-1 RNA, 32P-
labeled tRNA, or 32P-labeled minus strand Tar DNA (Tar2) and either
PrP or HIV-1 NCp7 were performed for 10 min at 37 °C in 10 ml of a
buffer containing 20 mM TriszHCl, pH 7.5, 30 mM NaCl, 0.2 mM MgCl2,
5 mM dithiothreitol, 0.01 mM ZnCl2, 5 units of RNasin (Promega), 1.5
pmol of RNA, 3 pmol of tRNA; or Tar(2) and PrP or NCp7 at the
indicated molar protein to nt ratios. Reactions were stopped by SDS/
EDTA (0.5%/5 mM), and samples were treated with proteinase K (2 mg)
for 10 min at room temperature, phenol-chloroform was extracted, and
RNA was analyzed by electrophoresis on 1.3% agarose in 50 mM
Triszborate, pH 8.3. Gels were visualized by ethidium bromide staining
FIG. 1. HIV-1 RNA sequences and functions of NCp7 in virus
replication. A, the 59- and 39-regions of the HIV-1 genomic RNA and
the TAR oligonucleotides are shown. The 59-leader RNA is made up of
several functional domains: TAR and poly(A) stem-loop structures are
required for provirus transcription and during reverse transcription for
minus strand DNA transfer. Note that the TAR and poly(A) domains
form R (Repeat). U5 is the untranslated 59-sequence. PBS is the primer
tRNA3
Lys binding site and is 18-nt long. PBS is also required for plus
strand DNA transfer. The DIS (dimer initiation sequence) and E/DLS
(packaging/dimer linkage element) are necessary for viral RNA dimer-
ization and packaging in assembling particles. AUG is the initiator
codon for Gag. The 39-RNA is formed of the PPT (polypurine track),
which is the start site for plus strand DNA synthesis, U3 (39-untrans-
lated sequences), the TAR and poly(A) stem-loop structures, and An tail
(broken line). The TAR and poly(A) are required for minus strand
transfer during proviral DNA synthesis. Nucleotide positions are indi-
cated above the lines representing the 59- and 39-RNAs. B, HIV-1 NCp7
and mutant NCp7-(12–53) with the two CCHC zinc fingers (Zn) are
shown. The complete huPrP as well as the N- and C-terminal regions
are shown with the octarepeats and the H1 to H4 helices. Amino acid
positions are indicated. Functions of NC in HIV-1 replication are me-
diated by nucleic acid interactions as indicated by arrows. In the course
of viral DNA synthesis NC chaperones primer tRNA annealing to the
primer binding site, initiation of reverse transcription, and completion
of viral DNA synthesis by RT. TAR and poly(A) are required for NC to
chaperone minus strand DNA transfer, and primer binding site for plus
strand DNA transfer. Also NC chaperones viral RNA dimerization and
packaging during virus assembly.
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followed by gel fixation in 5% trichloroacetic acid, drying, and autora-
diography. A 0.16- to 1.77-kb RNA ladder was used for size determina-
tion. The percentage of primer annealed to the HIV-1 RNA was deter-
mined by densitometric scanning of the autoradiograph.
Reverse Transcription Assays—First the nucleic acid annealing assay
was carried out in 10 ml for 5 min at 37 °C as above, and next the
reaction volume was increased to 25 ml by addition of 2 pmol of HIV-1
RT, 0.25 mM each of dNTPs, 60 mM NaCl, and 2.5 mM MgCl2. Samples
were incubated for 20 min at 37 °C. The reactions were stopped and
processed as for the analysis of nucleic acid annealing, except that after
phenol extraction, nucleic acids were ethanol-precipitated, recovered by
centrifugation, dissolved in formamide, denatured at 95 °C for 2 min,
and analyzed on 8% polyacrylamide gel electrophoresis in 7 M urea and
0.53 TBE, pH 8.3. 59-32P-Labeled FX174 DNA Hinf markers (Promega)
were used for size determination (not shown). The levels of cDNA
synthesized by RT were quantified by densitometric scanning.
Cell Culture, DNA Transfection, and Immunohistochemistry—293T
cells, derived from the HEK cell line (human embryonic kidney cells),
were cultured at 37 °C in an atmosphere of 5% CO2 and in Dulbecco’s
modified Eagle’s medium (Life Technologies, Inc.) complemented with
10% fetal calf serum, penicillin (100 IU/ml), streptomycin (100 mg/ml),
and L-glutamine (2 mM). Transfection of 293T cells were performed
using the calcium phosphate method with 3 mg of pDNA-huPrP for 106
cells. After 10 days under puromycin selection (0.7 mg/ml), resistant cell
colonies were expanded and found to express huPrP.
For immunohistochemistry, cells were grown in eight-well Labtek
chamber slides and fixed in ice-cold 2% paraformaldehyde for 30 min at
4 °C. They were then washed twice in PBS and incubated for 30 min in
a blocking solution of PBS containing 5% bovine serum albumin, 1%
normal goat serum, and 0.2% Tween 20 prior to staining with antibod-
ies. This same solution served to dilute the anti-PrP SAF 37 antibody
(IgG2a recognizing amino acids 79–92 of huPrP) used at 1/200 dilution,
and the rhodamine-conjugated Helix pomatia lectin, which was in-
cluded with the primary antibody in some experiments at a concentra-
tion of 5 mg/ml (kindly provided by Dr. F. Barde, ENS, Lyon, France).
Primary incubation was for 2 h at room temperature. After washing
sections 5 3 10 min in PBS, bound antibodies were revealed with
fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin
at a final dilution of 1/400 in blocking buffer containing bis-benzimide (1
mg/ml) to stain DNA. Controls included no primary antibody and non-
transfected cells. Slides were washed three times in PBS, mounted with
moviol and analyzed with a Zeiss axioplan fluorescence microscope, and
a Zeiss axiovert inverting microscope equipped with 488- and 514-nm
lasers and LSM 510 software for confocal analysis.
RESULTS
The Human and Ovine PrP Bind HIV-1 RNA in Vitro—
HIV-1 nucleocapsid protein NCp7 is a small Gag-encoded pro-
tein. During the infectious process NCp7 is required to chap-
FIG. 2. Formation of nucleoprotein complexes after binding of PrP to HIV-1 RNA. 32P-Labeled HIV-1 59-leader RNA of 415 nt in length
(described in Fig. 1) was incubated at 37 °C for 10 min with or without NCp7 or PrP. Formation of nucleoprotein complexes was analyzed by
electrophoresis on a 3% polyacrylamide gel in 50 mM Triszborate, pH 8.3. One picomole of RNA was used, and the molar ratios of protein to nt are
indicated at the top. Lanes 1, 5, 9, 13, 17, and 21, CT without protein; lanes 2–4, NCp7; lanes 6–8, NCp7-(12–53); lanes 10–12, ovine PrP (ovPrP);
lanes 14–16, human PrP (huPrP(23–231)); lanes 18–20, huPrP-(23–144); lanes 22–24, huPrP-(122–231). Vertical arrow is direction of electro-
phoresis. Horizontal arrows are free RNA and nucleoprotein complexes, respectively. Results shown indicate that binding of PrP or NCp7 to HIV-1
RNA is probably cooperative.
FIG. 3. Nucleic acid annealing activity of PrP. Assays were performed as indicated under “Experimental Procedures” with HIV-1 39-RNA
and 32P-labeled Tar(2) DNA (Fig. 1). At the end of the reaction, protein was removed by proteinase K digestion, followed by phenol extraction.
Analysis of 32P-Tar(2) annealed to HIV-1 39-RNA was by electrophoresis on 1.3% agarose gels. Gel was fixed with 5% trichloroacetic acid, dried,
and autoradiographed. The molar ratios of protein to nt are indicated at the top. The vertical arrow shows direction of electrophoresis and
horizontal arrows correspond to Tar(2) DNA (bottom) and HIV-1 39-RNA:Tar(2) DNA (middle). Lanes 1, 8, 12, 16, 20, control incubation without
NCp7 or PrP; lanes 2–4, NCp7; lanes 5–7, NCp7-(12–53); lanes 9–11, ovine PrP (ovPrP); lanes 13–15, huPrP-(23–231); lanes 17–19, huPrP-(23–144);
lanes 21–23, huPrP-(122–231).
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erone proviral DNA synthesis by reverse transcriptase (RT)
(Fig. 1A) (16, 18, 19). In addition, NCp7 is pivotal in virus
assembly, because it recruits the genomic RNA and chaperones
its dimerization and packaging into assembling particles (Fig.
1A). Interactions between the HIV-1 59-leader RNA and NCp7
appear to govern these viral processes (Fig. 1A). NCp7 with the
two zinc fingers and an NCp7 mutant, designated NCp7-(12–
53), without the basic N- and C-terminal domains necessary for
RNA dimerization in vitro and virus assembly in vivo (16, 24,
25), were generated by peptide synthesis (Fig. 1B and data not
shown) (23). Recombinant huPrP-(23–231) and the N (23–145)-
and C (122–231)-terminal regions were produced in E. coli and
purified to homogeneity (21). To compare the nucleic acid bind-
ing abilities of PrP and HIV-1 NCp7, we used the multifunc-
tional 59-leader of HIV-1 (Fig. 1), because it is formed of con-
tiguous functional domains that are required for viral DNA
transcription (TAR and poly(A) stem-loops), minus strand DNA
synthesis by RT (59-primer binding site for initiation and Tar
for strand transfer), viral RNA dimerization and packaging (DIS
and DLS), and translation (the AUG of Gag) (Fig. 1). NCp7
interacts with the DIS-DLS domains to chaperone viral RNA
dimerization and packaging during virus assembly and with the
59-primer binding site and TAR sequences during minus strand
DNA synthesis by RT in the course of infection (16, 19).
As observed previously (18), NCp7 binds in a cooperative
manner to the multifunctional 59-leader of HIV-1 RNA and
forms nucleoprotein complexes (Fig. 2, lanes 2–4), whereas the
NCp7 mutant (12–53) does not form stable complexes (lanes
6–8). huPrP binds to the 59-leader RNA as evidenced by the
formation of nucleoprotein complexes (lanes 14–16). The N-
terminal fragment (23–144) of huPrP was also able to bind to
the 59-leader RNA (lanes 18–20) in a manner similar to NCp7
(lanes 2–4), whereas the C-terminal fragment (122–231) did
not show any RNA binding affinity (lanes 22–24). The ovine
PrP was also expressed in E. coli as a recombinant protein and
purified to homogeneity (not shown). The ovine PrP also formed
nucleoprotein complexes in a dose-dependent manner similar to
NCp7 (lanes 10–12). These NC- and PrP-nucleoprotein com-
plexes are of high molecular mass, because they can be recovered
by 5-min centrifugation at 10,000 3 g (data not shown) (26).
Human and Ovine PrP Have Nucleic Acid Chaperoning
Properties—The interactions of PrP with nucleic acids sug-
gested that this cellular protein might have RNA and DNA
annealing activities similar to those of HIV-1 NCp7 or the
human p53 protein (27). This was examined using HIV-1 se-
quences corresponding to TAR and the 39-region of the HIV-1
FIG. 4. PrP directs HIV-1 RNA dimerization and annealing of primer tRNA3
Lys to the primer binding site. A, ethidium bromide
staining of the 1.3% agarose gel. B, autoradiography to show primer 32P-tRNA3
Lys annealing to HIV-1 primer binding site. The HIV-1 59-leader RNA
and 32P-labeled tRNA3
Lys were incubated at 37 °C with or without NCp7 or PrP and reactions were processed. The protein-to-nt molar ratios are
indicated at the top. The arrow shows direction of electrophoresis and markers (in nt) are indicated on the left. HIV-1 monomer, dimer and
multimer RNAs, and tRNA3
Lys are indicated on the right. Lanes 1 and 7, CT without protein. Lanes 2–4, with NCp7; lanes 5 and 6, with
NCp7-(12–53); lanes 8–10, with huPrP; lanes 11–13, with huPrP-(23–144); lanes 14 and 15, with huPrP-(122–231). Note that huPrP-(122–231) did
not promote HIV RNA dimerization or tRNA annealing to the primer binding site (lanes 14 and 15), whereas huPrP and huPrP-(23–144) were very
active.
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RNA genome corresponding to U3, TAR, and poly(A) sequences
(Fig. 1A). The minus strand TAR sequence (Tar2) represents
the 39-end of the so-called strong stop cDNA (ss-cDNA(2)), the
initial product of reverse transcription. Under physiological
conditions, NCp7 directed annealing of Tar2 to Tar1 present
within the 39-RNA (Fig. 3, lanes 2–4). Interestingly, huPrP was
also able to hybridize Tar2 to the 39-RNA in a dose-dependent
manner (lanes 13–15). A similar level of hybridization was
obtained with huPrP-(23–144) (lanes 17–19). On the other
hand, NCp7-(12–53) and huPrP-(122–231) did not direct an-
nealing of Tar2 to HIV-1 39-RNA (lanes 5–7 and 21–23, respec-
tively). The ovine PrP (ovPrP) was found to be as effective as
huPrP and HIV-1 NCp7 in directing the specific annealing
reaction (lanes 9–11). These data demonstrate that PrP of
human or ovine origin has nucleic acid annealing activity char-
acteristic of HIV-1 NCp7 and retroviral NC proteins in general
(16, 18, 19, 27–30).
PrP Chaperones HIV-1 RNA Dimerization and Annealing of
Primer tRNA to the Primer Binding Site—In the viral particle,
the retroviral genome is dimeric and has replication primer
tRNA annealed to the primer binding site, which constitutes
the start site for reverse transcription (see Fig. 1A). As dem-
onstrated before, genomic RNA dimerization and tRNA anneal-
ing to the primer binding site are promoted by NC protein. In
control experiments we used well characterized nucleic acid
binding proteins of viral origin such as retroviral reverse tran-
scriptases (RT), HIV-1 Vpr and integrase, T4 gp32 or nucleic
acid binding proteins of cellular origin like E. coli RecA and
human p53. All these proteins, some of which have nucleic acid
chaperone properties (40), were found to be inactive in these
viral processes (see Refss 18 and 23 for RTs and E. coli RecA;
Ref. 27 for human p53 or RT). Using the HIV-1 system with the
multifunctional 59-leader RNA and primer tRNA3
Lys (Fig. 1B)
NCp7 was indeed critical for HIV-1 RNA dimerization and
primer tRNA3
Lys annealing to the primer binding site (Fig. 4, A
and B, lanes 2–4) (18, 23). Interestingly, we found for the first
time that a cellular protein, namely PrP, was capable of pro-
moting HIV-1 RNA dimer formation and tRNA3
Lys annealing to
the primer binding site in a dose-dependent manner (lanes
14–16 for huPrP). Very similar data were obtained with the N
FIG. 5. PrP chaperones initiation of
reverse transcription of HIV-1 RNA.
A, a scheme to show reverse transcription
initiation of HIV-1 RNA and synthesis of
minus strand strong stop cDNA,
ss-cDNA(2), where PBS stands for
primer binding site. B, HIV-1 59-RNA and
32P-labeled tRNA3
Lys were incubated with
or without NCp7 or PrP. HIV-1 RTp66-
p51 was added together with the dNTPs
to allow reverse transcription initiation.
Reactions were processed, and ss-
cDNA(2) was analyzed. The protein-to-nt
molar ratios are indicated above the fig-
ure. The arrow shows the direction of
electrophoresis, and markers (in nt) are
indicated on the left. The ss-cDNA-tRNA
and primer tRNA3
Lys are indicated on the
right. Lanes 1 and 7, CT with RT but
without NCp7 or huPrP. Lanes 2–4, with
NCp7; lanes 5 and 6, with NCp7-(12–53);
lanes 8–10, with huPrP; lanes 11–13, with
huPrP-(23–144); lanes 14 and 15, with
huPrP-(122–231); lanes 16 and 17, with
ovine PrP (ovPrP). Note that even at a
high molar ratio of huPrP-(122–231)
ss-cDNA was not synthesized (lane 15).
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terminus (23–144) of huPrP (lanes 18–20). NCp7-(12–53) re-
tained little activity (lanes 6–8) (16) and the C-terminal frag-
ment (122–231) of huPrP was completely inactive (lanes 22–
24). The ovine PrP (ovPrP) was also found to show an NC-like
activity, because it directed HIV-1 RNA dimerization and primer
tRNA3
Lys annealing to the primer binding site (lanes 10–12).
Reverse transcription of the viral RNA is initiated by RT-
mediated extension of the primer tRNA hybridized to the
primer binding site by NCp7 (Figs. 1A and 5A). NCp7 was
indeed critical for the initiation of minus strand cDNA synthe-
sis (Fig. 5B, compare lanes 1 and 2–4) (1–3, 16). Once again,
huPrP was found to duplicate the properties of NCp7 by ac-
tively promoting initiation of reverse transcription in a dose-
dependent fashion (Fig. 5B, lanes 8–10). The N-terminal frag-
ment (23–144) of huPrP exhibited part of this activity (lanes
11–13). NCp7-(12–53) retained some activity, but only at a high
protein to nt ratio (lanes 5 and 6, protein to nt molar ratio of
1:3) (16). The C-terminal fragment (122–231) of huPrP was
completely inactive (lanes 14 and 15). Similarly to huPrP, the
full-length ovine PrP was also very active in chaperoning the
initiation of reverse transcription (lanes 16 and 17).
PrP Promotes Specific Proviral DNA Synthesis—A succes-
sion of specific events is required for the conversion of the
genomic RNA into a complete proviral DNA with the two LTRs.
Nevertheless, nonspecific replicative events can take place,
such as self-initiation of reverse transcription, which is en-
hanced by template interactions, nicks in the genome or folding
back of the template (31–33). Retroviral NC proteins behave as
nucleic acid chaperones, which can destabilize RNA secondary
structures and thus inhibit self priming of reverse transcrip-
tion (see scheme in Fig. 6A) (31–33).
A 650-nt RNA, with a 25-nt poly(A) tail, corresponding to the
39-region of the HIV-1 genomic RNA was used to mimic re-
sumption of minus strand cDNA synthesis after minus strand
transfer (Fig. 1B) (31–34). However, a possibility exists that RT
transcribes the genomic RNA by virtue of self-priming at the
39-end and thus in the absence of minus strand transfer after
ss-cDNA synthesis (Fig. 6A). As shown in Fig. 6B and in agree-
ment with published data (31, 32) NCp7 strongly inhibited
self-primed cDNA synthesis in a dose-dependent manner (lanes
2 and 3), whereas the zinc finger domain (NCp7-(12–53)) was
completely inactive in this process (lanes 5 and 6). Interest-
ingly, PrP of both human and ovine origins strongly inhibited
self-priming of cDNA synthesis (lanes 8–9 and 17–18, respec-
FIG. 6. PrP inhibits self-priming of
reverse transcription. A, self-priming
of reverse transcription is shown in Ref. 1.
Coating of the free RNA by NCp7 or PrP,
which results in the inhibition of self-
priming is schematized in Ref. 2. B, self-
priming of reverse transcription. Assays
with HIV-1 39-RNA were performed as
described under “Experimental Proce-
dures” except that [32P]dCTP was used.
The protein-to-nt molar ratios are indi-
cated at the top. The vertical arrow on the
right shows direction of electrophoresis
and DNA markers (in nt) are indicated.
Lanes 1, 4, 7, 10, 13, and 16 are CT with-
out added protein; lanes 2 and 3, NCp7;
lanes 5 and 6, NCp7-(12–53); lanes 8 and
9, huPrP-(23–231); lanes 11 and 12, hu-
PrP-(23–144); lanes 14 and 15, huPrP-
(122–231); lanes 17 and 18, ovine PrP
(ovPrP).
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tively), and this activity mapped to the N terminus (positions
23–144) and not the C terminus (positions 122–231) (lanes
11–12 and 14–15, respectively).
To examine the continuation of cDNA synthesis by reverse
transcription of HIV-1 39-RNA after minus strand transfer, the
Tar2 DNA representing the 39-region of ss-cDNA(2) was in-
cluded in the assays (Fig. 7A). Under these physiological con-
ditions (see “Experimental Procedures”) both NCp7 and PrP
were able to hybridize Tar2 to HIV-1 39-RNA (Fig. 3). Exten-
sion of Tar2 by reverse transcription of the 39-RNA was clearly
specific in the presence of HIV-1 NCp7 (Fig. 7B, compare lane
1 CT with lane 3 where the NCp7:nt ratio was 1:6; see also Fig.
6B) in agreement with published data (30, 31). PrP of either
ovine or human origin was found to completely replace NCp7,
because in both cases specific cDNA(2) synthesis was observed
(Fig. 7B; compare CT lane 1, with lane 7 (ovPrP-to-nt ratio of
1:6) and lane 9 (huPrP-to-nt ratio of 1:6). In addition, the N
terminus of huPrP was also functional in these assays (see lane
10 in which the huPrP-(23–144)-to-nt ratio was 1:6). Mutant
NCp7-(12–53) started to be partially effective at a protein-to-nt
molar ratio of 1:3 (lane 5). However, huPrP-(122–231) was
completely inactive in promoting specific cDNA synthesis
(lanes 12 and 13).
Subcellular Localization of PrP—The above results clearly
show that PrP has the ability not only to interact with nucleic
acids (Fig. 2) but also to modify their conformation (Fig. 5) and
chaperone the hybridization of nucleic acids with complemen-
tary sequences (Fig. 3) that are critical for HIV-1 replication
(Figs. 3–6). PrP is thought to localize mainly at the cell surface
of PrP-expressing cells (4, 6). This would render interactions
between PrP and cellular or viral nucleic acids unlikely. How-
ever, PrP has also been reported to localize to the Golgi and the
nucleus (8, 35). To examine the subcellular localization of PrP,
we used the 293T cells derived from a human embryonic kidney
cell line. Endogenous expression of PrP in these cells is below
the threshold of detection by immunocytochemistry, and no
staining was observed in control 293T cells (Fig. 8, A and B).
This allowed us to be confident that staining of transfected PrP
in 293T cells was selective, giving an accurate picture of its
subcellular distribution other than being nonspecific reactivity
against other cellular proteins. 293T cells were transfected
with a huPrP plasmid construct, and a 293T cell population
FIG. 7. PrP chaperones-specific
cDNA synthesis by RT. A, schemes
showing reverse transcription by self-
priming (lane 1 in B) and primer-directed
cDNA synthesis (lanes 3, 7, 9, and 11 in
B). B, primer-directed reverse transcrip-
tion of HIV-1 RNA. Assays were per-
formed in the presence of HIV-1 39-RNA
and primer Tar(2) DNA (see Fig. 2) and
in conditions described under “Experimen-
tal Procedures” except that [32P]dCTP
was used (31). The protein-to-nt molar ra-
tios are indicated at the top. The vertical
arrow shows the direction of electrophore-
sis and DNA markers (in nt) are indi-
cated. The horizontal arrow shows the
full-length cDNA. Lanes 1, CT without
added protein; lanes 2 and 3, NCp7; lanes
4 and 5, NCp7-(12–53); lanes 6 and 7,
ovine PrP; lanes 8 and 9, huPrP-(23–231);
lanes 10 and 11, huPrP-(23–144); lanes 12
and 13, huPrP-(122–231).
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constitutively expressing PrP was derived upon puromycin se-
lection. Both 293T and 293T-huPrP cells were examined by
immunocytochemistry using an antibody recognizing amino
acids 79–92 of huPrP (SAF 37, J. Grassi, Commissariat a`
l’Energie Anatomique Saclay, France). As reported in Fig. 8,
intense punctate staining of huPrP occurred in the plasma
membrane of many cells, as was expected, but also in a cyto-
plasmic compartment and more rarely in what appeared to be
the nucleus (Fig. 8, C and D). In cells undergoing mitosis, as
determined by the organization of chromatin revealed by DNA
staining, a quite different pattern of expression was seen. In
such cells there was an intense staining throughout the cyto-
plasm. This was clearly not an artifact, because metaphase
control cells showed no staining (compare A with C). Confocal
analysis with double labeling of PrP and a Golgi marker (rho-
damine-conjugated H. pomatia lectin) showed that, in cells not
undergoing mitosis, PrP was selectively localized in the plasma
membrane and an intracellular compartment, including the
Golgi, although cytoplasmic PrP staining did not co-localize
very well with the Golgi marker (Fig. 8, E, G, and I, from the
plasma membrane to the nucleus). When nuclear staining of
PrP appeared to occur, the Golgi marker was also present,
indicating that in such cells the Golgi compartment was super-
imposed on the nucleus. In cells undergoing mitosis, the cyto-
plasmic localization of PrP was confirmed. Indeed the Golgi is
dispersed during mitosis, and it was apparent that PrP was not
so uniformly localized as the Golgi marker, indicating that PrP
is probably present in both the Golgi and a distinct cytoplasmic
compartment (vertical arrows in E–J). In conclusion, these data
strongly suggest that huPrP can accumulate in several cell
compartments where it might interact with nucleic acids.
DISCUSSION
The findings that PrP of human or ovine origin binds RNA
confirm and extend previous data showing that the human
prion protein exhibits nucleic acid binding properties (13–15).
Furthermore, we have found that binding of PrP to HIV-1 RNA
causes the formation of condensed nucleoprotein structures
similar to those obtained with retroviral NC proteins. Interest-
ingly, the interactions between PrP and the viral RNA in these
nucleoprotein structures appear to share many of the specific
functional characteristics of HIV-1 NCp7 in the viral context
(see below) (16, 20). PrP differs from other nucleic acid binding
proteins and nucleic acid chaperone proteins, because it mimics
the functions of NCp7 in HIV-1 replication such as HIV-1 RNA
dimerization and primer tRNA3
Lys annealing to the 59-primer
binding site during virus assembly and the chaperoning of
proviral DNA synthesis by RT during virus infection (see Figs.
1, 4, and 5) (reviewed in Ref. 16). The latter properties are not
shared by nucleic acid binding proteins such as HIV-1 Vpr and
RT, or human p53 (see Figs. 5–7 and Refs. 18, 26, 27, 32, 33, and
data not shown). Many cellular proteins with nucleic acid chap-
eroning properties are essential to nucleic acid maintenance and
metabolism (36), such as DNA repair for p53 (37), pre-mRNA
processing for hnRNP proteins (38), and telomere elongation for
hnRNP A1 (39). This suggests that PrP may exert one of its
functions at the level of nucleic acid metabolism (36, 40).
The length and precise location of the functional domain
responsible for the nucleic acid binding and chaperoning activ-
ities of PrP is at present unknown. However, our data clearly
show that this domain is localized within the N-terminal region
encompassing residues 23–144 (Figs. 3–7) (41) analogous to a
mutant PrP associated with a variant of the GSS syndrome (9).
The capacity of PrP to interact with nucleic acids (RNA,
DNA, and oligonucleotides) and to modify their conformation
and degree of compactness as well as to chaperone nucleic acids
interactions in a manner characteristic of retroviral NC pro-
FIG. 8. Localization of PRP in 293T cells. 293T cells expressing
human PrPC (C–J) were analyzed by immunocytochemistry for the
expression of PrP. In control 293T cells (A and B) no staining was
observed and background was very low. In 293T cells stably expressing
huPrP, we observed strong staining of PrP in the membrane and cell
body (see arrowheads in C and D). Cytoplasmic staining was intense
throughout the cytoplasm of cells determined to be in metaphase by
DNA staining with bis-benzimide (B and D). This was not simply a cell
cycle-related artifact, because no staining occurred in metaphase cells
that were not transfected with the huPrP plasmid (compare cells indi-
cated by arrowheads in A and B with those in C and D). Confocal
microscopy was performed to analyze the subcellular distribution of
PrP in stained cells (E–J). The same cells are shown at three different
depths in the Z axis (going progressively deeper from the cell membrane
to the nucleus). Green fluorescence shows anti-PRP staining, and red
fluorescence shows binding of the H. pomatia lectin to show the Golgi (E,
G, and I), close co-localization appears as yellow labeling. Phase con-
trast in F, G, and H corresponds to the immunofluorescent staining in
E, G, and I, respectively. The vertical downward pointing arrow indi-
cates a cell that was established to be in metaphase by DNA labeling
(not shown). Note the round morphology and absence of a defined
nuclear compartment under phase contrast. The cell indicated by the
horizontal arrow was apparently not in metaphase, because it contains
a well defined nucleus and typical fusiform morphology with a short
process. In cells that were not undergoing mitosis, huPrP was localized
primarily in the membrane and also in a cellular compartment depicted
by the Golgi label (red fluorescence). Co-localization, indicated by yellow
staining was not perfect, and often patches and points of green anti-PrP
staining occurred in the midst of a patch of red Golgi staining (blue
arrows in E and G). In the metaphase cell the Golgi stain was dispersed
quite evenly throughout the majority of the cell body, although it was
excluded from the region occupied by the chromatin (unstained region of the
metaphase cell in G and I). PrP staining was also diffuse and cytoplasmic;
however, intense points and patches of labeling occurred in the cytoplasm
with a distribution distinct from that of the more evenly distributed Golgi
label. Occasionally, PrP staining appeared to occur in the nucleus, as indi-
cated by the blue arrows in G and H, however, the Golgi label also stained
and co-localized in the same region suggesting that the apparent nuclear
labeling may well be in a distinct overlying compartment.
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teins (Figs. 5–7) (16, 42, 43) raises a number of questions. PrP
is found in several cell compartments. A major fraction is
usually attached to the plasma membrane via the GPI anchor.
However, a transmembrane form with the N terminus in the
cytosol, designated ctmPrP, has also been described (44). In
addition to accumulation in the plasma membrane, huPrP was
also found in the cytosol and probably in the nucleus, where it
might interact with cellular and/or viral nucleic acids (Fig. 8).
PrP may thus belong to a growing class of proteins exhibiting
numerous activities and functions, for example the 37-kDa
laminin receptor precursor (45). The latter protein is present on
the cell surface as well as in a form associated with ribosomes
as a component of the mRNA translational machinery (46, 47).
Interestingly, PrP interacts with this 37-kDa laminin receptor
precursor (45). Another example of a protein with both mem-
brane- and nucleic acid-associated functions is C17. This
protein is either membrane-associated, functioning in G-pro-
tein-mediated signal transduction related to the calcitonin
gene-related receptor (48) or associated with RNA polymerase
III for tRNA gene transcription (49). The possibility that PrP is
associated with ribosomes or other cellular nucleoprotein com-
ponents is presently under investigation.
In cells infected by HIV-1, the retroviral Gag polyprotein
encoding NC is membrane-anchored via its N terminus during
virion formation and budding at the cell surface (16, 25, 43, 50).
Therefore, it is tempting to speculate that Gag and PrP interact
at the plasma membrane in infected cells. This might well
influence virus replication and accelerate the scrapie infectious
process as suggested by Carp et al. (17) in the MuLV/mouse
system. In that respect, the impact of huPrP expression on
HIV-1 formation and replication is currently being investi-
gated, and preliminary results indicate that PrP interactions
with NC and the viral RNA can strongly influence HIV-1 virion
formation and replication.
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